FT538 is an off-the-shelf NK cell cancer immunotherapy created from a clonal master iPSC line engineered to prevent expression of the cell surface protein, CD38. FT538 is being developed for use in combination with FDA-approved agents that are used early and often in the treatment of cancer, such as DARZALEX® (daratumumab), an FDA-approved anti-CD38 monoclonal antibody.
CD38 is broadly expressed on natural killer (NK) cells, as well as myeloma cells. As a result, NK cells can be significantly depleted in patients treated with anti-CD38 antibodies. However, NK cells are known to be important for the antitumor activity of anti-CD38 antibodies via the antibody dependent cellular cytotoxicity mechanism (ADCC). This is supported by preclinical and clinical data that suggests a potential therapeutic benefit of maintaining NK cell number and function in patients treated with anti-CD38 antibodies.
We are developing FT538 for enhanced ADCC in combination with anti-CD38 antibodies, such as daratumumab. FT538 is designed to provide a robust population of NK cells resistant to depletion when used in combination with anti-CD38 antibodies, thereby improving outcomes for patients with multiple myeloma.